Home › Pancreatic Cancer › NCT05625529

ExoLuminate Study for Early Detection of Pancreatic Cancer

Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* ≥18 years old.
* Meeting criteria for one of the study cohorts.
* Capable of giving informed consent.
* Able to provide a blood sample.

Exclusion Criteria:

* \< 18 years old.
* Pregnancy.
* Active cancer (other than pancreatic cancer) and/or undergoing treatment for an active cancer diagnosis (except for skin malignancies).
* Prior organ transplant or bone marrow transplant.
* History of fainting or other adverse effects when blood is drawn.
* Any condition that, in the opinion of the investigator, should preclude enrollment.

About the study

ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC).

Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis.

The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.

Sponsor: Biological Dynamics · Participants: 1,000 · Started: Dec 19, 2022

Contact the study team

• Harmeet Dhani, MD, M.Sc · Phone: 858-202-6150

Official record on ClinicalTrials.gov — NCT05625529

Locations in the U.S.

Conditions

• Pancreatic Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.